Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

PURPOSE: Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features achieve poor outcomes with traditional therapies. A phase I study of a pharmacokinetically derived schedule of flavopiridol suggested promising activity in CLL, irrespective of high-risk features. Given the rel...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lin, Thomas S., Ruppert, Amy S., Johnson, Amy J., Fischer, Beth, Heerema, Nyla A., Andritsos, Leslie A., Blum, Kristie A., Flynn, Joseph M., Jones, Jeffrey A., Hu, Weihong, Moran, Mollie E., Mitchell, Sarah M., Smith, Lisa L., Wagner, Amy J., Raymond, Chelsey A., Schaaf, Larry J., Phelps, Mitch A., Villalona-Calero, Miguel A., Grever, Michael R., Byrd, John C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2009
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2793044/
https://ncbi.nlm.nih.gov/pubmed/19826119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.6944
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak